1-10 of 10
Thomas Budd
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Open Access
Avia D. Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, Carley Mitchell, Paul G. Pavicic, Jr, Pingfu Fu, Amit Rupani, Hana Husic, Patricia A. Rayman, Shadi Swaidani, Jame Abraham, G. Thomas Budd, Halle Moore, Zahraa Al-Hilli, Jennifer S. Ko, Joseph Baar, Timothy A. Chan, Tyler Alban, C. Marcela Diaz-Montero, Alberto J. Montero
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 82–93.
https://doi.org/10.1158/1078-0432.CCR-23-1349
Published: 05 January 2024
View articletitled, Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Open the PDF for Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Free
Brian I. Rini, Jorge A. Garcia, Matthew M. Cooney, Paul Elson, Allison Tyler, Kristi Beatty, Joseph Bokar, Tarek Mekhail, R.M. Bukowski, G. Thomas Budd, Pierre Triozzi, Ernest Borden, Percy Ivy, Helen X. Chen, Afshin Dowlati, Robert Dreicer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-09-0717
Published: 30 September 2009
View articletitled, A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Open the PDF for A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors in another window
Journal Articles

Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients

Free
David G. Hicks, Brian J. Yoder, Sarah Short, Shannon Tarr, Nichole Prescott, Joseph P. Crowe, Andrea E. Dawson, G. Thomas Budd, Steven Sizemore, Muzaffer Cicek, Toni K. Choueiri, Raymond R. Tubbs, Daniel Gaile, Norma Nowak, Mary Ann Accavitti-Loper, Andra R. Frost, Danny R. Welch, Graham Casey
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (22): 6702–6708.
https://doi.org/10.1158/1078-0432.CCR-06-0635
Published: 22 November 2006
View articletitled, Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients
Open the PDF for Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients in another window
Journal Articles

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

Free
G. Thomas Budd, Massimo Cristofanilli, Mathew J. Ellis, Allison Stopeck, Ernest Borden, M. Craig Miller, Jeri Matera, Madeline Repollet, Gerald V. Doyle, Leon W.M.M. Terstappen, Daniel F. Hayes
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6403–6409.
https://doi.org/10.1158/1078-0432.CCR-05-1769
Published: 03 November 2006
View articletitled, Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Open the PDF for Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer in another window
Journal Articles

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Free
Daniel F. Hayes, Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, Alison Stopeck, M. Craig Miller, Jeri Matera, W. Jeffrey Allard, Gerald V. Doyle, Leon W.W.M. Terstappen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4218–4224.
https://doi.org/10.1158/1078-0432.CCR-05-2821
Published: 20 July 2006
View articletitled, Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Open the PDF for Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival in another window
Journal Articles

The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course

Free
Brian J. Yoder, Elisa Tso, Marek Skacel, Jim Pettay, Shannon Tarr, Thomas Budd, Raymond R. Tubbs, Josephine C. Adams, David G. Hicks
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 186–192.
https://doi.org/10.1158/1078-0432.186.11.1
Published: 21 January 2005
View articletitled, The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course
Open the PDF for The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course in another window
Journal Articles

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Free
Carol J. Fabian, Bruce F. Kimler, Julie Anderson, Ossama W. Tawfik, Matthew S. Mayo, William E. Burak, Jr., Joyce A. O’Shaughnessy, Kathy S. Albain, David M. Hyams, G. Thomas Budd, Patricia A. Ganz, Edward R. Sauter, Samuel W. Beenken, William E. Grizzle, John P. Fruehauf, Dora W. Arneson, James W. Bacus, Michael D. Lagios, Karen A. Johnson, Doris Browne
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5403–5417.
https://doi.org/10.1158/1078-0432.CCR-04-0171
Published: 24 August 2004
View articletitled, Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator
Open the PDF for Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator in another window
Journal Articles

Breast Tumor Immunophenotype of BRCA1 -Mutation Carriers Is Influenced by Age at Diagnosis

Free
Susan A. J. Vaziri, Lisa M. Krumroy, Paul Elson, G. Thomas Budd, Gerarda Darlington, Jonathan Myles, Raymond R. Tubbs, Graham Casey
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1937–1945.
Published: 01 July 2001
View articletitled, Breast Tumor Immunophenotype of BRCA1 -Mutation Carriers Is Influenced by Age at Diagnosis
Open the PDF for Breast Tumor Immunophenotype of BRCA1 -Mutation Carriers Is Influenced by Age at Diagnosis in another window
Journal Articles

Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis

Free
Rosalind van Stolk, Gary Stoner, William L. Hayton, Kenneth Chan, Barry DeYoung, Laura Kresty, Brian H. Kemmenoe, Paul Elson, Lisa Rybicki, James Church, Kim Provencher, Denise McLain, Ernest Hawk, Ben Fryer, Gary Kelloff, Ram Ganapathi, G. Thomas Budd
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 78–89.
Published: 01 January 2000
View articletitled, Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis
Open the PDF for Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis in another window
Journal Articles

Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma

Free
Ronald M. Bukowski, Patricia Rayman, Luis Molto, Charles S. Tannenbaum, Thomas Olencki, David Peereboom, Raymond Tubbs, Denise McLain, G. Thomas Budd, Thomas Griffin, Andrew Novick, Thomas A. Hamilton, James Finke
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 2780–2789.
Published: 01 October 1999
View articletitled, Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma
Open the PDF for Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma in another window